Essential Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Essential Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69	Closed	-$2.78K	–	2860
2026 Q1	$2.78K	Sell	69 -5,038	-99%	-$109K	﹤0.01%	1857
2025 Q4	$128K	Sell	5,107 -12,652	-71%	-$297K	0.04%	387
2025 Q3	$402K	Sell	17,759 -6,143	-26%	-$143K	0.13%	202
2025 Q2	$414K	Buy	+23,902	New	+$442K	0.17%	178

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Essential Partners's APLS Position: Q2 2026 in Review

Essential Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 69 shares — an estimated $2.78K sold.

Essential Partners first reported a position in APLS in Q2 2025 and held it in 4 quarters. The position peaked at $414K in Q2 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Essential Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Essential Partners sold 69 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.78K.
Essential Partners first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Essential Partners's Apellis Pharmaceuticals position peaked at $414K in Q2 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.